Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
VistaGen Therapeutics Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 36 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $0.88 |
|---|---|
| 52-week range | $0.86 - $3.46 |
| 50-day moving average | $1.13 |
| 200-day moving average | $1.68 |
| Wall St. target price | $7.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.34 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.875 from 2022-07-05
| 1 week (2022-06-30) | -0.57% |
|---|---|
| 1 month (2022-06-03) | N/A |
| 3 months (2022-04-07) | -31.10% |
| 6 months (2022-01-04) | -55.58% |
| 1 year (2021-07-07) | -72.83% |
|---|---|
| 2 years (2020-07-07) | 65.50% |
| 3 years (2019-07-05) | 24.29% |
| 5 years (2017-07-06) | 1.8 |
| Revenue TTM | $1.1 million |
|---|---|
| Gross profit TTM | $1.1 million |
| Return on assets TTM | -32.65% |
| Return on equity TTM | -58.62% |
| Profit margin | 0% |
| Book value | $0.31 |
| Market capitalisation | $181.8 million |
TTM: trailing 12 months
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.86 up to $3.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.9505. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license agreement with Pherin Pharmaceuticals, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.